This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Implied Volatility Surging for Keros Therapeutics Stock Options
by Zacks Equity Research
Investors need to pay close attention to KROS stock based on the movements in the options market lately.
KROSPositive Net Change
biotechnology biotechs medical
Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings?
by Ekta Bagri
Strong performance of Asceniv continues to boost ADMA. We recommend the stock to investors due to its solid long-term fundamentals.
GRFSNegative Net Change ADMANegative Net Change TAKPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
by Zacks Equity Research
MDGL stock is rising as it reports better-than-expected first-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
BAYRYNegative Net Change BEAMNegative Net Change ADMANegative Net Change MDGLNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down
by Zacks Equity Research
BHCs first-quarter 2025 adjusted earnings and revenues miss estimates. Salix performs lower than expected. Stock declines.
BEAMNegative Net Change FOLDPositive Net Change ADMANegative Net Change BHCPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
UTHR Q1 Earnings & Revenues Beat Estimates on Higher Tyvaso Sales
by Zacks Equity Research
United Therapeutics reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven mainly by strong Tyvaso sales.
BAYRYNegative Net Change UTHRPositive Net Change BEAMNegative Net Change ADMANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Company News for Apr 30, 2025
by Zacks Equity Research
Companies In The News Are: NUE, REGN, PYPL, PFE.
REGNPositive Net Change PFENegative Net Change NUENegative Net Change PYPLNegative Net Change
basic-materials biotechnology business-services pharmaceuticals
Should You Buy, Sell or Hold GILD Stock Post Q1 Earnings Miss?
by Ekta Bagri
GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the oncology business is under pressure. We advise investors to remain on the sidelines at current levels.
GSKNegative Net Change MRKPositive Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
These 5 Buy-Ranked Mid-Cap Stocks Are Flying High Year to Date
by Nalak Das
Five mid-cap high-flying stocks to buy are: ADMA, FCFS, LRN, LTH, NFG.
FCFSNegative Net Change NFGNegative Net Change LRNNegative Net Change ADMANegative Net Change LTHNegative Net Change
biotechnology consumer-discretionary finance oil-energy
Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down
by Zacks Equity Research
REGN reports lower-than-expected Q1 results. Lead drug Eylea sales plunge in the United States due to competition. Stock down.
REGNPositive Net Change SNYPositive Net Change RHHBYNo Net Change BAYRYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales
by Zacks Equity Research
Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
NVSPositive Net Change LLYPositive Net Change BAYRYNegative Net Change INCYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO's first-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.
NVONegative Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Eldorado Gold Corporation (EGO) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
EGONegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Novartis Beats on Q1 Earnings and Sales, Raises Guidance, Stock Up
by Zacks Equity Research
NVS' first-quarter earnings and sales beat estimates. Based on the strong momentum of its key drugs, the company raises its annual guidance. Share price rises.
NVSPositive Net Change RHHBYNo Net Change PFENegative Net Change BAYRYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
StoneCo Ltd. (STNE)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
STNENegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
BMY Falls 4% Post Q1 Earnings: Should You Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers' first-quarter performance and raised annual guidance are encouraging. However, we recommend investors to stay on the sidelines as generic competition for legacy drugs and recent pipeline setbacks weigh on the stock.
BMYNegative Net Change PFENegative Net Change MRKPositive Net Change
biotechnology biotechs earnings-report medical pharmaceuticals
Zoetis Gears Up to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
ZTS' higher companion animal product sales are likely to have driven revenues in first-quarter 2025 in both the United States and International segments.
NVAXPositive Net Change ZTSNegative Net Change CTMXNegative Net Change ARGXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?
by Zacks Equity Research
Investors will likely focus on the demand for Cabometyx and pipeline updates when EXEL reports Q1 results.
AZNPositive Net Change VRTXNegative Net Change EXELPositive Net Change ARGXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
RXRX is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter 2025 earnings release, given the absence of a marketed product.
NVAXPositive Net Change CTMXNegative Net Change ARGXPositive Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline
by Zacks Equity Research
Gilead Sciences' Q1 earnings and sales miss estimates on lower oncology drug sales. The stock is trading down.
GSKNegative Net Change GILDNegative Net Change ANIPPositive Net Change ADMANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
CytomX Gears Up to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
On the Q1 2025 earnings call, investors can expect updates regarding the progress in the development of CTMX's lead candidate, CX-2051, for colorectal cancer.
AMGNPositive Net Change NVAXPositive Net Change CTMXNegative Net Change ARGXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
BMY Beats on Q1 Earnings and Sales, Raises 2025 Outlook
by Zacks Equity Research
BMY beats on both earnings and sales in the first quarter of 2025. The company raises its guidance for the full year.
BMYNegative Net Change PFENegative Net Change ANIPPositive Net Change ADMANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?
by Ahan Chakraborty
Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.
NVONegative Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy Regulus (RGLS) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More
by Ekta Bagri
BMY and REGN are in the spotlight this week following study data and regulatory updates, respectively.
REGNPositive Net Change SNYPositive Net Change BMYNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Buy 5 High ROE Stocks as Markets Break Tariff-Induced Losing Streak
by Supriyo Bose
CBOE, AGNC, JAZZ, AES and CNSWF are some of the stocks with high ROE to profit from as markets expect the tariff war to end soon.
AGNCNegative Net Change AESNegative Net Change CBOENegative Net Change JAZZNegative Net Change CNSWFNegative Net Change
biofuels biotechnology fin-tech finance reit tech-stocks